Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Öhman, Procuritas, Spiltan and others in connection with the acquisition of 51.1 per cent of the shares in Emric AB
Mandate

Vinge advises Öhman, Procuritas, Spiltan and others in connection with the acquisition of 51.1 per cent of the shares in Emric AB

June 10, 2010

Vinge is advising KB Götaberg 20 (Öhman), Investmentbolaget av 1 maj 2009 AB (Procuritas), Investment AB (Spiltan), Norra Brofästet i Sundsvall AB and F. Månsson Invest AB in connection with the acquisition of 50.1 per cent of the shares in Emric AB from Bisnode AB. Emric is one of Sweden's leading providers of software, expert consultancy and outsourcing services to the banking and financial services sector. The acquisition is based on a call option which was issued in connection with Bisnode's purchase of 50.1 per cent of the shares in Emric in 2007.
 
Vinge's team advising the buyers consists of partner Henrik Wenckert and associates Marie Brommesson and Peter Sundgren.

Related

Vinge advised Precise Biometrics

 Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

 Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026